BTG Shoots For $1 Billion Revenue Stars In On-Going Transformation
The specialist health care company is building a multi-asset interventional medicines business that it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
You may also be interested in...
BTG's CEO says combining novel immuno-oncology therapies with image-guided, minimally invasive therapies could deliver treatments where needed while lowering overall treatment costs.
BTG of Britain plans two new acquisitions, including a therapy for liver cancer that uses radioactive glass beads and a treatment for dissolving severe blood clots. The deals create an interventional medicine business with potential sales of $1 billion; BTG is funding much of the exercise through a share placement.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.